Axonics Modulation Technologies Inc (NASDAQ:AXNX) Position Cut by JPMorgan Chase & Co.

Share on StockTwits

JPMorgan Chase & Co. lessened its holdings in shares of Axonics Modulation Technologies Inc (NASDAQ:AXNX) by 0.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 235,441 shares of the company’s stock after selling 846 shares during the quarter. JPMorgan Chase & Co.’s holdings in Axonics Modulation Technologies were worth $5,638,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of AXNX. Citigroup Inc. bought a new stake in Axonics Modulation Technologies during the 4th quarter valued at approximately $28,000. Barclays PLC bought a new stake in Axonics Modulation Technologies during the 4th quarter valued at approximately $31,000. American International Group Inc. bought a new stake in Axonics Modulation Technologies during the 4th quarter valued at approximately $69,000. Deutsche Bank AG bought a new stake in Axonics Modulation Technologies during the 4th quarter valued at approximately $137,000. Finally, Brightworth bought a new stake in Axonics Modulation Technologies during the 1st quarter valued at approximately $274,000. 29.44% of the stock is currently owned by institutional investors.

AXNX has been the subject of several research analyst reports. SunTrust Banks raised their price target on Axonics Modulation Technologies to $26.00 and gave the company a “buy” rating in a report on Tuesday, March 5th. Zacks Investment Research cut Axonics Modulation Technologies from a “hold” rating to a “sell” rating in a report on Monday, May 6th. Finally, Bank of America raised their price target on Axonics Modulation Technologies from $30.00 to $35.00 and gave the company a “buy” rating in a report on Thursday. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Axonics Modulation Technologies presently has a consensus rating of “Buy” and an average price target of $25.78.

NASDAQ AXNX opened at $34.21 on Friday. The company has a market cap of $898.85 million and a price-to-earnings ratio of -7.37. The company has a debt-to-equity ratio of 0.16, a current ratio of 22.83 and a quick ratio of 22.07. Axonics Modulation Technologies Inc has a 1-year low of $11.95 and a 1-year high of $34.87.

Axonics Modulation Technologies (NASDAQ:AXNX) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.07). The business had revenue of $1.08 million during the quarter, compared to analyst estimates of $0.53 million. As a group, research analysts forecast that Axonics Modulation Technologies Inc will post -2.03 EPS for the current fiscal year.

In other Axonics Modulation Technologies news, COO Rinda Sama sold 13,345 shares of the firm’s stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $28.03, for a total transaction of $374,060.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

COPYRIGHT VIOLATION WARNING: “Axonics Modulation Technologies Inc (NASDAQ:AXNX) Position Cut by JPMorgan Chase & Co.” was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/4371260/axonics-modulation-technologies-inc-nasdaqaxnx-position-cut-by-jpmorgan-chase-co.html.

Axonics Modulation Technologies Company Profile

Axonics Modulation Technologies, Inc, a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, including urinary urgency incontinence and urinary urgency frequency, fecal incontinence, and urinary retention.

Featured Article: Moving Average – How it Helps Investors in Stock Selection

Want to see what other hedge funds are holding AXNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axonics Modulation Technologies Inc (NASDAQ:AXNX).

Institutional Ownership by Quarter for Axonics Modulation Technologies (NASDAQ:AXNX)

Receive News & Ratings for Axonics Modulation Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics Modulation Technologies and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Alliance Data Systems Co.  Receives Average Rating of “Hold” from Brokerages
Alliance Data Systems Co. Receives Average Rating of “Hold” from Brokerages
Host Hotels and Resorts Inc  Receives Consensus Recommendation of “Buy” from Analysts
Host Hotels and Resorts Inc Receives Consensus Recommendation of “Buy” from Analysts
Weir Group PLC  Given Consensus Rating of “Buy” by Analysts
Weir Group PLC Given Consensus Rating of “Buy” by Analysts
ViaSat, Inc.  Receives $96.99 Average Target Price from Analysts
ViaSat, Inc. Receives $96.99 Average Target Price from Analysts
Carrefour SA  Given Consensus Rating of “Hold” by Brokerages
Carrefour SA Given Consensus Rating of “Hold” by Brokerages
RTL Group S.A.  Receives €53.23 Consensus Target Price from Analysts
RTL Group S.A. Receives €53.23 Consensus Target Price from Analysts


© 2006-2019 Ticker Report